Design Therapeutics Inc. (DSGN)
NASDAQ: DSGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
DSGN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $731.58M
- EPS (TTM)
- -$1.18
- Dividend yield
- None
- 52-week range
- 5.28 – 17.25
- Day range
- 11.58 – 12.06
- Volume / Avg
- 344.45K / 607.69K
- Beta
- —
- Shares outstanding
- 62.58M
- Next earnings
- Nov 4, 2026
52-week range
DSGN stock today
Design Therapeutics (DSGN) closed at $11.69 on Oct 7, down 2.34% (-$0.28), versus the S&P 500's 0.22% decline. At this level, DSGN sits in the middle of its 52-week range of $5.28 to $17.25: 32.2% below the high, set on Apr 29, 2026 and 121.4% above the low. DSGN is up 24.6% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 80.1%.
Design Therapeutics has posted a net loss over the last twelve months (EPS of -$1.18), so its P/E ratio is not meaningful. Design Therapeutics's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Design Therapeutics
Company profileDesign Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Pratik Shah Ph.D.
- Headquarters
- Carlsbad, CA
- Employees
- 55
- IPO year
- 2021
- Website
- designtx.com
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$21.71+85.71%
- Strong buy 2
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $-0.38
Design Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AVTXAvalo Therapeutics Inc. | 13.58 | -0.07% | $728.30M | vs DSGN |
| GYREGyre Therapeutics Inc. | 7.04 | -0.56% | $746.48M | vs DSGN |
| VSTMVerastem Inc. | 8.27 | +6.65% | $748.51M | vs DSGN |
| COLLCollegium Pharmaceutical Inc. | 21.93 | +0.23% | $713.94M | vs DSGN |
| APMDApnimed Inc. | 18.04 | -3.27% | $751.02M | vs DSGN |
| ANNXAnnexon Inc. | 4.01 | -0.50% | $760.21M | vs DSGN |
| WVEWave Life Sciences Inc. | 3.54 | +0.57% | $697.55M | vs DSGN |
| HELPHelus Pharma Inc. | 10.51 | -2.32% | $767.86M | vs DSGN |
Indexes, lists and sector
Design Therapeutics stock FAQ
What is Design Therapeutics's stock price today?
DSGN last traded at $11.69 as of Oct 7, 4:00 PM EDT, down 2.34% on the day. Prices are delayed at least 15 minutes.
When is Design Therapeutics's next earnings date?
Design Therapeutics is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $-0.38.
Who is Design Therapeutics's CEO?
Mr. Pratik Shah Ph.D. is the chief executive officer of Design Therapeutics Inc., which has about 55 employees.
What is the DSGN 52-week high?
The 52-week high for DSGN is $17.25 and the 52-week low is $5.28. The stock is currently 32.2% below its high.